August 7, 2023
Alan joined Fulcrum in August 2023 as Chief Financial Officer. Prior to joining Fulcrum, Alan served for several years as CFO of ReViral, which was acquired by Pfizer in 2022. Previously, he was the Chief Financial Officer and Treasurer at Peloton Therapeutics Inc., where he secured a $150 million mezzanine financing and prepared the company for a NASDAQ IPO until the company was acquired by Merck & Co. Alan also served as CFO and Treasurer of other biopharmaceutical companies, including Bellicum Pharmaceuticals, Targacept, and Duramed Pharmaceuticals. He spent the early part of his career as a senior internal auditor for Pfizer as well as a Certified Public Accountant (CPA) for KPMG International.
Alan received a B.S. in Accounting from Saint Mary’s College California and a master’s degree from the American Graduate School of International Management. He currently serves on the Board of Directors for Lung Therapeutics, Inc.